The past 6 months have been difficult for the developers of CCR5 antagonists. First, GlaxoSmithKline halted Phase III studies of aplaviroc because of serious hepatotoxicity (ACC Sep 28 2005), and then ...
Am J Health Syst Pharm. 2009;66(8):715-726. Mechanism of action of maraviroc. Before fusion of the HIV viral envelope and host cell membrane can occur, an HIV glycoprotein complex consisting of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results